cd7.car/28zeta car t cells
T-cell Malignancies
Beijing GoBroad HospitalCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the T-cell Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
New Donor-Derived Cd7 Car T-Cell Beijing GoBroad Hospital | Phase 1/2 | CC |
Autologous Cd7 Car T-Cell Beijing GoBroad Hospital | Phase 1/2 | CC |
Prior-Hsct Donor-Derived Cd7 Car T-Cell Beijing GoBroad Hospital | Phase 1/2 | CC |
Same molecule, other indications
cd7.car/28zeta car t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →